Business Wire

Schlumberger New Energy, the CEA and Partners Announce Appointment of CEO of Genvia, a Clean Hydrogen Production Technology Venture

Share

Schlumberger New Energy, the CEA and partners have announced Florence Lambert as the CEO of the Genvia clean hydrogen production technology venture, effective March 1, 2021. Florence brings more than 20 years of experience in new energy technologies and was previously CEO of CEA-LITEN in Grenoble, France.

“Florence has been a respected voice at the forefront of energy transition technology development for a number of years. We are delighted that she has chosen to bring her experience and passion to the leadership of Genvia. We believe that hydrogen is a critical energy carrier that will enable countries to meet their decarbonization ambitions,” said Ashok Belani, Executive Vice President Schlumberger New Energy.

In the next 30 years, hydrogen production could account for 20% of total energy demand, according to the Hydrogen Council. Genvia’s technology development and industrialization activities will be in step with the anticipated strong growth of the hydrogen economy. Genvia will provide innovative early solutions through strategic alliances in different industries.

“Genvia brings together an extraordinary group of partners, to foster the new ecosystem needed to accelerate the development and industrialization of affordable clean hydrogen production. I am particularly delighted to have the opportunity with Genvia to create business and employment growth while making an impact on climate change,” said Florence Lambert, the newly appointed Genvia CEO.

The Genvia Board of Directors will have high-level executive representation from its founding partners:

  • François Jacq, Chairman and Philippe Stohr, Energy Division Director, CEA
  • Ashok Belani, Executive Vice President New Energy, and Olivier Peyret, Chairman of France, Schlumberger
  • Guy Sidos, Chairman and CEO, Vicat
  • Pascal Baylocq, CEO Geostock, (VINCI Construction)
  • Simon Munsch, Services Director, Occitanie Region.

The Genvia high-performance solid oxide electrolyzer technology developed by the CEA is fully reversible, giving it the flexibility to switch between electrolysis and fuel cell functions. Genvia technology design will enable a 30% higher electricity conversion efficiency per kg of hydrogen produced, bringing the cost of producing clean hydrogen down to a level that competes aggressively with other sources of energy.

Leveraging Schlumberger technology industrialization experience, the first Genvia manufacturing pilot line will be established at a Schlumberger manufacturing facility in Béziers in 2021. Genvia will also set up a Technology Centre co-located with the CEA in Grenoble, France, to accelerate the maturing of the technology through the industrialization process.

Genvia will participate in a series of demonstration projects with partners in different use cases for the industrial, energy and mobility sectors. These demonstration projects will pave the way for the development of the full value chain for the utilization of hydrogen as the clean energy carrier of choice. The different demonstration projects are expected to range from 300 kW systems in 2023 to larger systems with megawatt capacities in 2024.

Based on the results of the pilot line and demonstration projects, investment into the building of a giga factory for the production of solid oxide electrolyzer and fuel cell stacks is expected to launch in 2025. The production ramp of the giga factory will enable Genvia to meet the gigawatt deliveries of electrolyzers and fuel cells, which the market is anticipated to demand at an accelerated pace in 2030 and beyond.

About Schlumberger New Energy

Schlumberger is the world's leading provider of technology to the global energy industry. Schlumberger New Energy explores new avenues of growth by leveraging Schlumberger’s intellectual and business capital in emerging new energy markets, with a focus on low-carbon and carbon-neutral energy technologies. Its activities include ventures in the domains of hydrogen, lithium, carbon capture and sequestration, geothermal power and geoenergy for heating and cooling buildings.

About CEA

The CEA is a key player in research, development and innovation in four main areas: energy transition, digital transition, technology for the medicine of the future and defense and security. With a workforce of 20,000 people, based in nine French sites equipped with very large-scale research infrastructures, the CEA actively participates in collaborative projects with a large number of academic and industrial partners, in France, Europe and worldwide. According to the Clarivate 2019 ranking, the CEA is the first French research organization, in terms of number of patents filed in France and Europe.

The CEA invested through its fully owned subsidiary CEA Investissement, a unique tool for a public research organization. It is assisted and operated by Supernova Invest, the CEA’s private equity partner, which brings its in-depth experience of cutting-edge technologies towards more than 140 investments in deeptech companies, including in the hydrogen industry.
www.cea.fr
www.supernovainvest.com

About VINCI Construction

A subsidiary of VINCI, VINCI Construction, is a global player and European leader, active on five continents, with more than 72,000 employees and 830 companies generating revenue of €14.9 billion in 2019. Structured according to an integrated model, the company has the capacity to intervene over the entire life cycle of a structure (finance, design, construction, maintenance) in eight sectors: buildings, functional structures, transport infrastructure, hydraulic engineering, renewable and nuclear energy, the environment, hydrogen and gas sector, and mines.
www.vinci-construction.com

About Vicat

With almost 200 years of experience, the Vicat Group develops a top-class offering of mineral and bio-based construction materials. In following the trajectory it has set itself for carbon neutrality throughout its value chain, the Group operates three core lines of business: Cement, Ready-Mixed Concrete and Aggregates, as well as related activities. Still family-run, the Company has almost 9,950 employees, and generated consolidated sales of €2.7 billion in 2019. The Group operates in twelve countries: France, Switzerland, Italy, the United States, Turkey, Egypt, Senegal, Mali, Mauritania, Kazakhstan, India and Brazil. More than 60% of its sales are generated outside France.
www.vicat.com

About AREC, an investment company in the Occitanie Region

Tool of the Occitanie Region, AREC suggests energy transition solutions to territories. The Agency endeavors to offer actors adapted solutions, whether they are turnkey or specific, depending on the contexts of the actors in the territories of Occitanie. Neutral, it has an objective vision of solutions. A trusted third party for regional actors and serving the general interest, AREC's added value lies in its unique support across the entire energy transition value chain: from upstream to the realization and financing of projects. The Occitanie Region has also always positioned itself as a pioneer in the development of the hydrogen sector in its territory. This wish was illustrated in 2019 by the adoption of an unprecedented Green Hydrogen Plan, endowed with €150 million, which should make it possible to achieve the objective of becoming the leading positive energy region in Europe by 2050. AREC has actively participated in the deployment of the “green hydrogen” sector in the region since 2016, as an actor of the energy transition in Occitanie. The Agency provides technical support and invests in innovative production and distribution projects in order to deploy hydrogen ecosystems that respect the environment. Thus, AREC is already involved in major projects in Occitanie such as the HyPort project and the Hyd'Occ project.
www.arec-occitanie.fr

Cautionary Statement Regarding Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the U.S. federal securities laws — that is, statements about the future, not about past events. Such statements often contain words such as “expect,” “may,” “believe,” “plan,” “estimate,” “intend,” “anticipate,” “should,” “could,” “will,” “likely,” “goal,” and other similar words. Forward-looking statements address matters that are, to varying degrees, uncertain, such as the extent to which hydrogen will account for the world’s future energy demands; zero emissions goals, anticipated growth of the hydrogen economy and the level of acceptance of hydrogen in global decarbonization, greenhouse gas (“GHG”) emissions reduction goals and other forecasts or expectations regarding global climate change. These statements are subject to risks and uncertainties, including, but not limited to, the level of acceptance of hydrogen in global decarbonization; the inability to achieve net zero goals; the inability to recognize intended benefits of Genvia’s business strategies and initiatives; the inability to produce hydrogen at costs competitive to other sources of energy; legislative and regulatory initiatives addressing environmental concerns, including initiatives addressing the impact of global climate change; and other risks and uncertainties detailed in the companies’ public filings, including Schlumberger’s most recent Forms 10-K, 10-Q, and 8-K filed with or furnished to the U.S. Securities and Exchange Commission. If one or more of these or other risks or uncertainties materialize (or the consequences of such a development changes), or should underlying assumptions prove incorrect, actual outcomes may vary materially from those reflected in our forward-looking statements. The forward-looking statements speak only as of the date of this press release, the parties disclaim any intention or obligation to update publicly or revise such statements, whether as a result of new information, future events or otherwise.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media
Giles Powell – Director of Corporate Communication, Schlumberger Limited
Tel: +1 (713) 375-3494
communication@slb.com

Tuline Laeser – CEA
Tel: +33 1 64 50 20 97
presse@cea.fr

Investors
Ndubuisi Maduemezia – Vice President of Investor Relations, Schlumberger Limited
Joy V. Domingo – Director of Investor Relations, Schlumberger Limited
Tel: +1 (713) 375-3535
investor-relations@slb.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 18:03:00 CEST | Press release

Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio

Vertex Announces European Commission Approval for KALYDECO ® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 17:43:00 CEST | Press release

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)

Suzano 2023 annual report on Form 20-F26.4.2024 17:22:00 CEST | Press release

Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/Contact information Hawthorn Advisors suzano@hawthornadvisors.com

Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer26.4.2024 14:30:00 CEST | Press release

Takeda (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of fruquintinib, a selective inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2 and -3 for the treatment of adult patients with previously treated metastatic colorectal cancer (mCRC). The European Commission (EC) will consider the CHMP positive opinion when determining the potential marketing authorization for fruquintinib for mCRC throughout the European Union (EU), Norway, Liechtenstein and Iceland. If approved, fruquintinib will be the first and only selective inhibitor of all three VEGF receptors approved in the EU for previously treated mCRC.1,2 “People living with metastatic colorectal cancer in the European Union currently have limited treatment options, which can lead to poor outcomes. With this positive opinion for fruquintinib, we are one step closer to potentially offering patients a new

MEDIA ALERT: Wolters Kluwer expert comments on European Parliament vote to pass amendment implementing Basel III reforms26.4.2024 14:00:00 CEST | Press release

The European financial landscape saw a milestone event this week, as the EU Parliament passed the Amendment to Regulation (EU) No 575/2013, implementing the Basel III finalization within Europe. This monumental step forward comes with the adoption of the Capital Requirements Regulation (CRR3) amendments, which are part of a broader legislative package, including amendments to Directive 2013/36/EU, known as the Capital Requirements Directive or CRD. Jeroen Van Doorsselaere, Vice President of Global Product & Platform Management, Wolters Kluwer FRR, said: “The adoption of the Capital Requirements Regulation (CRR3) amendments represents a landmark change for the banking industry, designed to strengthen the framework for risk-based capital requirements and address ESG risks. “This is a major overhaul of the capital requirements framework, impacting various aspects, including credit risk, operational risk, market risk, and the capital floor. Whereas other significant jurisdictions, includin

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye